A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Trial Profile

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2018

At a glance

  • Drugs AMG 397 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 16 May 2018 Planned End Date changed from 13 Sep 2020 to 14 Oct 2020.
    • 16 May 2018 Planned primary completion date changed from 13 Sep 2020 to 14 Oct 2020.
    • 16 May 2018 Planned initiation date changed from 15 May 2018 to 15 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top